Obviousness

Obviousness Analysis of U.S. Patent 12,252,506 under 35 U.S.C. § 103

Washington, D.C. – An analysis of U.S. Patent 12,252,506 has been conducted to assess the obviousness of its claims in light of the cited prior art. Under 35 U.S.C. § 103, a patent claim is unpatentable if the differences between the claimed invention and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art (POSITA).

A POSITA in the field of this invention would be a medicinal or organic chemist, likely with a Ph.D., possessing significant experience in nucleoside chemistry, synthetic methodologies, and the principles of pharmaceutical salt selection and preparation.

Based on the prior art, the independent claims of the '506 patent appear vulnerable to an obviousness rejection through the combination of existing references. The primary prior art references—WO 2007/061798 (Sauve), Tanimori et al., and Franchetti et al.—all teach the synthesis of nicotinamide riboside (NR) culminating in a trifluoromethanesulfonate (triflate or -OTf) salt. The '506 patent itself, along with the Sauve reference, explicitly identifies the problem with the triflate salt: its unsuitability for human consumption due to toxicity. This acknowledgment in the prior art provides a clear and direct motivation for a skilled artisan to modify the existing process to produce a pharmaceutically acceptable salt form.

---

Analysis of Composition Claims (Claims 1 and 6)

Claim 1: This claim covers NR compounds (formula IV) with a specific set of anions, excluding formate and triflate.
Claim 6: This claim is narrower, specifically covering NR compounds where the anion is from an aminodicarboxylic acid (e.g., glutamate, aspartate).

Obviousness Argument:

A straightforward argument for the obviousness of claims 1 and 6 can be constructed by combining the teachings of WO 2007/061798 (Sauve) with established principles of pharmaceutical chemistry.

1. Motivation to Combine: The Sauve reference discloses a method to produce the NR cation but explicitly notes that the resulting triflate salt is not ideal for nutritional supplements. This provides a clear reason for a POSITA to improve upon Sauve's work by replacing the toxic triflate anion with one suitable for human consumption. Pharmaceutical salt selection is a routine practice aimed at improving properties like stability, solubility, and toxicity. A skilled chemist would be directly motivated to find a non-toxic, stable salt form for the NR cation disclosed by Sauve.

2. Reasonable Expectation of Success: The anions claimed in the '506 patent, such as acetate, lactate, ascorbate, and amino acid-derived anions like aspartate and glutamate, are well-known in the pharmaceutical industry and are generally recognized as safe (GRAS). The process of forming different salts of a known cationic molecule is a standard and predictable procedure in medicinal chemistry. A POSITA would have a high degree of confidence that the NR cation could be successfully paired with these common, non-toxic anions to form stable salts. The inventive step is not the creation of the NR cation itself (taught by Sauve), but rather its combination with a specific, safe anion. This act of swapping a known toxic anion for a known safe anion would likely be considered an obvious and routine step in drug or supplement development.

Therefore, starting with the NR triflate from Sauve, it would have been obvious to a POSITA to prepare various pharmaceutically acceptable salts, including those recited in claims 1 and 6, to solve the toxicity problem.

---

Analysis of Method Claims (Claims 13 and 18)

Claim 13 & 18: These claims describe a method for converting an isomerically pure NR triflate salt into a different salt form by reacting it with a compound Z+X-, where Z+ is a nitrogen-containing cation.

Obviousness Argument:

The method claims are similarly obvious by combining the teachings of WO 2007/061798 (Sauve) with standard, well-known chemical techniques for ion exchange.

1. Motivation to Combine: As established, Sauve provides the motivation to replace the triflate anion. The problem then becomes how to perform this replacement. While Sauve suggests chromatography, this is often a costly and inefficient method for large-scale production. A POSITA would be motivated to find a more direct and scalable chemical method. Salt metathesis, or ion exchange reaction, is a fundamental and common technique for this exact purpose.

2. Reasonable Expectation of Success: The specific method claimed—reacting the triflate salt with a Z+X- salt where Z+ is a nitrogen-containing cation—is a textbook example of a salt metathesis reaction. The use of an ammonium salt (where Z+ is NH4+) is one of the most common ways to introduce a new anion. For example, to create nicotinamide riboside chloride, reacting the triflate salt with ammonium chloride is a logical and straightforward approach. A skilled chemist would expect this reaction to proceed to or towards equilibrium, yielding the desired chloride salt. This is not a complex or unpredictable reaction but rather a direct application of fundamental chemical principles to solve the known problem of anion replacement. The choice of a nitrogen-containing cation like ammonium is a routine and obvious one for a chemist performing such an anion swap.

Conclusion

The claims of U.S. Patent 12,252,506 appear to be obvious under 35 U.S.C. § 103. The prior art explicitly identified the toxicity problem associated with the triflate salt of nicotinamide riboside. The solutions claimed in the '506 patent—both the resulting compositions with safe anions and the chemical method to produce them—represent routine and predictable steps that a person of ordinary skill in the art would have taken to solve this known problem. The selection of common, pharmaceutically acceptable anions and the use of a standard salt metathesis reaction for anion exchange do not appear to rise to the level of a non-obvious inventive step.